Patrys completes successful clinical trial
THE PHARMACY: Patrys Limited (ASX: PAB) has received final results from a Phase I/IIa, open-label study of PAT-SM6 in patients with refractory or relapsed multiple myeloma (MM). Patrys explained the trial was conducted in 12 patients (10 male and 2 female, median age 71 years) with refractory or relapsed MM. The primary endpoint of the […]




